North America Cancer Diagnostics Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

October 2017 | 150 pages | ID: NB1DE7B7320EN
Data Bridge Market Research

Abstracts

In this region, North America cancer diagnostics is projected to reach USD 17.72 billion by 2024 from USD 7.59 billion in 2016, at a CAGR of 11.2% in the forecast period 2017 to 2024.

The major factors driving the growth of this market are the technological advancement in the field of early detection of cancer and high investment in cancer research by North America. These factors increase the demand for cancer diagnostic products.

Based on geography, the North America cancer diagnostics market is segmented into 5 geographical regions, such as,

• U.S.
• Mexico
• Canada

North America cancer diagnostics market competition by top players including

GE Healthcare is going to dominate the cancer diagnostics market, by imaging following with Siemens Healthcare GmbH along with others such as

• Hologic Inc.
• Becton, Dickinson & Company.

Thermo Fisher Scientific, Inc. is going to dominate the cancer diagnostics market, by platform based following with Illumina, Inc. along with others such as

• Roche Diagnostics
• Abbott Laboratories, Inc.
• QIAGEN.

The North America cancer diagnostics market is segmented on the basis of technology, application and geography.

On the basis of technology, North America cancer diagnostics market is segmented into 2 types, namely platform based and instrument based. In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 69.4%

Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others.

Cancer diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.

On the basis of application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF NORTH AMERICA CANCER DIAGNOSTICS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. GROWTH OF AGING POPULATION AND RISING PREVALENCE OF CANCER
  3.1.2. GOVERNMENT INITIATIVES FOR FUNDING AND AWARENESS ABOUT CANCER
  3.1.3. KEY PLAYERS FOCUSING ON STRATEGIC DECISIONS TO GAIN MARKET SHARE
  3.1.4. INCREASING PREVELANCE OF CANCER
3.2. RESTRAINTS
  3.2.1. STRINGENT REULATIONS IMPOSED BY INTERNATIONAL AND LOCAL AUTHORITIES
  3.2.2. SHORTAGE OF SKILLED AND TRAINED PROFESSIONALS
3.3. OPPORTUNITIES
  3.3.1. NANOTECHNOLOGY: FORTHCOMING REVOLUTION IN CANCER DIAGNOSIS
  3.3.2. ARTIFICIAL INTELLIGENCE AND THE IMMINENT HEALTH REVOLUTION
  3.3.3. GROWING MEDICAL TOURISM IN ASIA
3.4. CHALLENGES
  3.4.1. INCREASING RIVALRY AMONG THE COMPETITORS
  3.4.2. POOR ACCESS TO CANCER DETECTION AND HIGH TREATMENT COCTS IN LOWER INCOME COUNTRIES

4. PREMIUM INSIGHTS

5. EXECUTIVE SUMMARY

6. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. OVERVIEW
6.2. PLATFORM BASED
  6.2.1. POLYMERASE CHAIN REACTION(PCR)
  6.2.2. IN SITU HYBRIDIZATION (ISH)
  6.2.3. IMMUNOHISTOCHEMISTRY(IHC)
  6.2.4. NEXT GENERATION SEQUENCING (NGS)
  6.2.5. DNA MICROARRAYS
  6.2.6. FLOW CYTOMETRY
6.3. INSTRUMENT BASED
  6.3.1. IMAGING
    6.3.1.1. MAGENTIC RESONANCE IMAGING (MRI)
    6.3.1.2. CT(COMPUTED TOMOGRAPHY)
    6.3.1.3. POSITRON EMISSION TOMOGRAPHY- COMPUTED TOMOGRAPHY (PET-CT)
    6.3.1.4. MAMMOGRAPHY
    6.3.1.5. ULTRASOUND
  6.3.2. BIOPSY

7. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION

7.1. OVERVIEW
7.2. LUNG CANCER
7.3. BREAST CANCER
7.4. COLORECTAL CANCER
7.5. MELANOMA
7.6. OTHERS

8. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW
8.2. NORTH AMERICA CANCER DIAGNOSTICS MARKET
  8.2.1. U.S.CANCER DIAGNOSTICS MARKET
  8.2.2. CANADA CANCER DIAGNOSTICS MARKET
  8.2.3. MEXICO CANCER DIAGNOSTICS MARKET

9. NORTH AMERICA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

9.1. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS IMAGING MARKET
9.2. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS PLATFORM BASED MARKET

10. COMPANY PROFILES

10.1. C. R. BARD, INC.
  10.1.1. COMPANY OVERVIEW
  10.1.2. REVENUE ANALYSIS
  10.1.3. PRODUCT PORTFOLIO
  10.1.4. RECENT DEVELOPMENTS
10.2. ILLUMINA, INC.
  10.2.1. COMPANY OVERVIEW
  10.2.2. REVENUE ANALYSIS
  10.2.3. RECENT DEVELOPMENTS
  10.2.4. PRODUCT PORTFOLIO
10.3. QIAGEN
  10.3.1. COMPANY OVERVIEW
  10.3.2. REVENUE ANALYSIS
  10.3.3. RECENT DEVELOPMENTS
  10.3.4. PRODUCT PORTFOLIO
10.4. ABBOTT
  10.4.1. COMPANY OVERVIEW
  10.4.2. REVENUE ANALYSIS
  10.4.3. RECENT DEVELOPMENTS
  10.4.4. PRODUCT PORTFOLIO
10.5. SIEMENS HEALTHCARE GMBH
  10.5.1. COMPANY OVERVIEW
  10.5.2. REVENUE ANALYSIS
  10.5.3. RECENT DEVELOPMENTS
  10.5.4. PRODUCT PORTFOLIO
10.6. AGILENT TECHNOLOGIES
  10.6.1. COMPANY OVERVIEW
  10.6.2. REVENUE ANALYSIS
  10.6.3. PRODUCT PORTFOLIO
  10.6.4. RECENT DEVELOPMENTS
10.7. THERMO FISHER SCIENTIFIC INC.
  10.7.1. COMPANY OVERVIEW
  10.7.2. REVENUE ANALYSIS
  10.7.3. PRODUCT PORTFOLIO
  10.7.4. RECENT DEVELOPMENTS
10.8. BECTON, DICKINSON AND COMPANY
  10.8.1. COMPANY OVERVIEW
  10.8.2. REVENUE ANALYSIS
  10.8.3. PRODUCT PORTFOLIO
  10.8.4. RECENT DEVELOPMENTS
10.9. GE HEALTHCARE
  10.9.1. COMPANY OVERVIEW
  10.9.2. REVENUE ANALYSIS
  10.9.3. PRODUCT PORTFOLIO
  10.9.4. RECENT DEVELOPMENTS
10.10. F. HOFFMANN-LA ROCHE LTD
  10.10.1. COMPANY OVERVIEW
  10.10.2. REVENUE ANALYSIS
  10.10.3. PRODUCT PORTFOLIO
  10.10.4. RECENT DEVELOPMENTS
10.11. HOLOGIC INC.
  10.11.1. COMPANY OVERVIEW
  10.11.2. REVENUE ANALYSIS
  10.11.3. RECENT DEVELOPMENTS
  10.11.4. PRODUCT PORTFOLIO
10.12. KONINKLIJHE PHILIPS N.V.
  10.12.1. COMPANY OVERVIEW
  10.12.2. REVENUE ANALYSIS
  10.12.3. PRODUCT PORTFOLIO
  10.12.4. RECENT DEVELOPMENTS

11. RELATED REPORTS

List Of Tables

LIST OF TABLES

TABLE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
TABLE 3 NORTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 4 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 5 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
TABLE 6 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
TABLE 7 U.S.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
TABLE 8 U.S. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 9 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 10 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
TABLE 11 U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
TABLE 12 CANADA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
TABLE 13 CANADA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 14 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 15 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
TABLE 16 CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)
TABLE 17 MEXICO CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
TABLE 18 MEXICO PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 19 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 20 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)
TABLE 21 MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET SNAPSHOT (2017)
FIGURE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016)
FIGURE 3 NORTH AMERICA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2017)
FIGURE 4 NORTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024)
FIGURE 5 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024)